23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
07:00 , Jun 16, 2011 |  BC Innovations  |  Targets & Mechanisms

Meet the METs

Researchers at Queen Mary, University of London have found that blocking endocytosis could treat MET-mutant cancers resistant to current treatments. 1 Developing a safe way to inhibit the essential cellular process could prove challenging. Endocytosis...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer c-Met proto-oncogene (MET; HGFR); dynamin (DNM); clathrin (CLT) In vitro and mouse studies suggest inhibiting MET endocytosis could help treat...